Journal of Gynecologic Oncology · 2023 · 10 citations · 36 references
MedicineOncologyPathologyGynecologic OncologyHistologyTumor PathologyCancer DiagnosisOvarian CancerTumor CharacterizationTumor ClassificationTumor GradingTumor HistopathologyGene Ontology AnalysisHistological TypingHistopathologic SubtypingHistopathological Tumor ClassificationMesenchymal TransitionOvarian Tumor ClassificationSerous Ovarian TumorsTumor Histologic Subtyping
OBJECTIVE: We have established 4 histopathologic subtyping of high-grade serous ovarian cancer (HGSOC) and reported that the mesenchymal transition (MT) type has a worse prognosis than the other subtypes. In this study, we modified the histopathologic subtyping algorithm to achieve high interobserver agreement in whole slide imaging (WSI) and to characterize the tumor biology of MT type for treatment individualization. METHODS: Four observers performed histopathological subtyping using WSI of HGSOC in The Cancer Genome Atlas data. As a validation set, cases from Kindai and Kyoto Universities were independently evaluated by the 4 observers to determine concordance rates. In addition, genes highly expressed in MT type were examined by gene ontology term analysis. Immunohistochemistry was also performed to validate the pathway analysis. RESULTS: After algorithm modification, the kappa coefficient, which indicates interobserver agreement, was greater than 0.5 (moderate agreement) for the 4 classifications and greater than 0.7 (substantial agreement) for the 2 classifications (MT vs. non-MT). Gene expression analysis showed that gene ontology terms related to angiogenesis and immune response were enriched in the genes highly expressed in the MT type. CD31 positive microvessel density was higher in the MT type compared to the non-MT type, and tumor groups with high infiltration of CD8/CD103 positive immune cells were observed in the MT type. CONCLUSION: We developed an algorithm for reproducible histopathologic subtyping classification of HGSOC using WSI. The results of this study may be useful for treatment individualization of HGSOC, including angiogenesis inhibitors and immunotherapy.
36
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon, Chet Birger, Helga Thorvaldsdóttir et al. · Cell Systems · 2015 · 14.5K citations · Full text
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text
Medicine, Gynecology, Oncology +11